EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Organogenesis Holdings's Enterprise Value is €377.2 Mil.
Organogenesis Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €14.3 Mil. Therefore, Organogenesis Holdings's EV-to-FCF for today is 26.36.
The historical rank and industry rank for Organogenesis Holdings's EV-to-FCF or its related term are showing as below:
FRA:2PQ'
s EV-to-FCF Range Over the Past 10 Years
Min: -721.33 Med: -12.12 Max: 1004.17
Current: 25.15
During the past 11 years, the highest EV-to-FCF of Organogenesis Holdings was 1004.17. The lowest was -721.33. And the median was -12.12.
FRA:2PQ's EV-to-FCF is ranked worse than 55.44% of 561
companies
in the Drug Manufacturers industry
Industry Median: 20.16
vs FRA:2PQ: 25.15
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Organogenesis Holdings's PE Ratio (TTM) for today is calculated as:
Organogenesis Holdings's share price for today is €2.06.
Organogenesis Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.169.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organogenesis Holdings EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Organogenesis Holdings's EV-to-FCF falls into.
Organogenesis Holdings's current Enterprise Value is €377.2 Mil.
Organogenesis Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €14.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organogenesis Holdings (FRA:2PQ) has a EV-to-FCF of 26.36 as of Jul. 03, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Organogenesis Holdings and its competitors. According to the industry distribution chart, Organogenesis Holdings ranks #311 out of 561 companies in the Drug Manufacturers industry, placing it in the top 55.4%.
Is Organogenesis Holdings' EV-to-FCF too high?
Organogenesis Holdings' current EV-to-FCF is 26.36. The Drug Manufacturers industry median EV-to-FCF is 20.16. Organogenesis Holdings' value of 26.36 is 30.8% above this industry median. Based on the distribution chart, Organogenesis Holdings ranks #311 out of 561 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Organogenesis Holdings has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Organogenesis Holdings' EV-to-FCF compare to TKNO and AKBA?
According to the Drug Manufacturers industry distribution chart, Organogenesis Holdings ranks #311 out of 561 companies for EV-to-FCF. This places Organogenesis Holdings in the lower half of its industry. The industry median EV-to-FCF is 20.16. Organogenesis Holdings' value of 26.36 is 30.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.16, based on 561 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organogenesis Holdings's current EV-to-FCF of 26.36 is 30.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Organogenesis Holdings and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organogenesis Holdings's current EV-to-FCF is 26.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organogenesis Holdings stock overvalued right now?
Based on GuruFocus' analysis, Organogenesis Holdings (FRA:2PQ) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.68, compared to a current price of €2.06 — trading 23.1% below its estimated fair value. The current EV-to-FCF is 26.36 and 30.8% above the Drug Manufacturers industry median of 20.16. Organogenesis Holdings' overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Organogenesis Holdings (FRA:2PQ), the current EV-to-FCF is 26.36 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organogenesis Holdings (FRA:2PQ) Overvalued in 2026?
Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued.
The current stock price of €2.06 is trading 23.1% below its estimated GF Value™ of €2.68.
GuruFocus considers Organogenesis Holdings to be Modestly Undervalued.
Key valuation signals for FRA:2PQ:
EV-to-FCF: 26.36
GF Value™: €2.68 vs. price of €2.06 (23.1% below fair value)
Industry Position: 30.8% above the Drug Manufacturers median (#311 of 561)
No single metric tells the full story. See the FRA:2PQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
65GF Score
Get the complete analysis for FRA:2PQ
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2PQ has been successfully added to your 
